Financials in USD. Standardized financial statements.
A compact view of how Astellas Pharma Inc. turns revenue into operating income and net income.
| Metric | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $2.27T | $1.91T | $1.60T | $1.52T | $1.30T | $1.25T | $1.30T | $1.31T | $1.30T | $1.31T |
| Revenue Growth? | +18.6% | +19.2% | +5.6% | +17.2% | +3.7% | -3.9% | -0.4% | +0.5% | -0.9% | 0.0% |
| Cost of Revenue? | $577.24B | $349.21B | $292.49B | $326.79B | $281.29B | $269.83B | $297.90B | $327.26B | $330.09B | $356.34B |
| Gross Profit? | $1.69T | $1.56T | $1.31T | $1.19T | $1.01T | $979.70B | $1.00T | $979.09B | $970.23B | $955.33B |
| Gross Margin? | +74.6% | +81.7% | +81.8% | +78.5% | +78.3% | +78.4% | +77.1% | +74.9% | +74.6% | +72.8% |
| Operating Expenses? | $1.25T | $1.52T | $1.29T | $906.40B | $794.85B | $728.80B | $723.52B | $698.95B | $698.99B | $678.91B |
| Operating Income? | $445.01B | $41.04B | $25.52B | $285.43B | $155.69B | $136.05B | $279.42B | $280.14B | $271.24B | $276.42B |
| EBITDA? | $651.34B | $248.05B | $194.81B | $246.88B | $241.52B | $220.31B | $314.75B | $313.73B | $284.76B | $347.54B |
| Income Before Tax | $399.30B | $31.24B | $24.97B | $132.36B | $156.40B | $144.85B | $247.01B | $248.97B | $218.11B | $281.77B |
| Income Tax Expense | $90.14B | -$19.51B | $7.92B | $33.65B | $32.80B | $24.73B | $49.94B | $26.70B | $53.43B | $63.07B |
| Net Income? | $309.12B | $50.75B | $17.05B | $98.71B | $124.09B | $120.59B | $195.41B | $222.26B | $164.68B | $218.70B |
| EPS? | $172.56 | $28.35 | $9.51 | $54.24 | $67.08 | $64.93 | $104.15 | $115.05 | $81.11 | $103.69 |
| Diluted EPS? | $172.56 | $28.24 | $9.47 | $54.09 | $67.05 | $64.90 | $104.08 | $114.94 | $81.02 | $103.55 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality